Related Experiment Videos

Lipid-Lowering Treatment Patterns and Risk of Subsequent Cardiovascular Outcomes in Patients With Recent Coronary

Casey Gazda1, Pallavi B Rane2, Sasikiran Nunna3

  • 1From the Division of Cardiology, University of North Carolina School of Medicine, Chapel Hill, NC.

Critical Pathways in Cardiology
|June 25, 2026
PubMed

Insights

Lipid-lowering therapy use increased post-revascularization, but high-intensity statins were underused. Many patients still had high LDL-C levels, indicating a need for better lipid management to prevent cardiovascular events.

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Background:

  • Lipid-lowering therapy (LLT) significantly reduces cardiovascular events (CVE) in patients with coronary artery disease.
  • Understanding LLT, LDL-C levels, and recurrent CVE after coronary revascularization is crucial for patient outcomes.

Purpose of the Study:

  • To investigate the utilization of lipid-lowering therapy (LLT) and low-density lipoprotein cholesterol (LDL-C) levels in patients following coronary revascularization.
  • To assess the rates of recurrent cardiovascular events (CVE) in relation to LLT and LDL-C control post-revascularization.

Main Methods:

  • Retrospective analysis of deidentified claims data from 2014-2019, including IQVIA PharMetrics Plus®, longitudinal prescription claims, and Prognos LDL-C database.
  • Identification of adult patients who underwent coronary revascularization, with analysis of LLT utilization, statin intensity, and LDL-C levels pre- and post-procedure.

Main Results:

  • LLT utilization increased from 46.0% pre-revascularization to 92.7% post-revascularization; however, only 56.4% received high-intensity statins.
  • Mean LDL-C decreased from 108 mg/dL pre- to 82 mg/dL post-revascularization, but 55.7%-62.1% of patients remained above 70 mg/dL.
  • Cardiovascular event rates at 12 months post-revascularization were 5.2/100 patient-years for MI, 2.0 for stroke, and 6.6 for unstable angina.

Conclusions:

  • Despite increased LLT use, high-intensity statin underutilization and persistent high LDL-C levels (>70 mg/dL) in over half of patients were observed post-revascularization.
  • Systematic interventions are necessary to optimize lipid control and reduce recurrent cardiovascular events after coronary revascularization.
Abstract

Keywords:
cardiovascular eventscoronary revascularizationlow-density lipoprotein cholesterolreal-world evidence

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...